^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Adrenal Cortex Carcinoma
    Drug:Lysodren (mitotane) (Steroid receptor inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    Scottish Medicines Consortium
    Title:

    Mitotane (Lysodren) is not recommended for use within NHS Scotland

    Published date:
    11/10/2006
    Excerpt:
    CONTRADICTING EVIDENCE: Mitotane (Lysodren) is not recommended for use within NHS Scotland for the symptomatic treatment of advanced (unresectable, metastatic or relapsed) adrenal cortical carcinoma.
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    04/28/2004
    Excerpt:
    Symptomatic treatment of advanced (unresectable, metastatic or relapsed) adrenal cortical carcinoma. The effect of Lysodren on non-functional adrenal cortical carcinoma is not established.
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    LYSODREN is an adrenal cytotoxic agent indicated for the treatment of inoperable, functional or nonfunctional, adrenal cortical carcinoma.
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Adrenocortical Carcinoma: other recommended regimen... Mitotane
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    ESMO.org
    Excerpt:
    In most patients with metastatic ACC, first-line therapy with mitotane alone or mitotane plus ChT is recommended; EDP-M is the first-line treatment of choice…